Next Generation Monoclonal Antibody Platform
Kymab is a “platform to product” biopharmaceutical company engaged in the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.
Technology Platform
Kymouse™ is a multi-strain, in vivo human monoclonal antibody discovery platform for the creation of fully human monoclonal antibodies and for testing the resulting mAbs in an in vivo preclinical setting. It is designed to provide the full spectrum of functional human immunoglobin diversity whilst retaining normal mouse B-cell signalling and maturation.
Partnering
Our technology is based on research from the world-leading Wellcome Trust Sanger Institute and is being commercialised with substantial financial backing from the Wellcome Trust. Our broad and flexible technology partnering strategy provides access to Kymouse™ through Target Focus and Access Plus commercial collaborations, as well as Academic Access.